Severe Combined Immunodeficiency Due to DCLRE1C Deficiency

Immunology·MeSH: Glucosephosphate Dehydrogenase Deficiency

Prevalence

5.0 / 100K

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target Severe Combined Immunodeficiency Due to DCLRE1C Deficiency?

There are 1 clinical trial targeting Severe Combined Immunodeficiency Due to DCLRE1C Deficiency tracked by BioSniper.

What is the prevalence of Severe Combined Immunodeficiency Due to DCLRE1C Deficiency?

The estimated prevalence of Severe Combined Immunodeficiency Due to DCLRE1C Deficiency is approximately 5.0 per 100,000 population.

Deep-dive into Severe Combined Immunodeficiency Due to DCLRE1C Deficiency

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Severe Combined Immunodeficiency Due to DCLRE1C Deficiency — Drugs in Development & Clinical Trials | BioSniper